Therapeutic efficacy and safety of combined BRAF and MEK inhibition in patients with malignant melanoma: a meta-analysis

References

• MartinliberalJLarkinJVemurafenib for the treatment of BRAF mutant metastatic melanomaFuture Oncol201511457958925686114
   PubMedGoogle Scholar
• ShiHHugoWKongXAcquired resistance and clonal evolution in melanoma during BRAF inhibitor therapyCancer Discov201441809324265155
   PubMed Web of Science ®Google Scholar
• ChapmanPBHauschildARobertCImproved survival with vemurafenib in melanoma with BRAF V600E mutationN Engl J Med2011364262507251621639808
   PubMed Web of Science ®Google Scholar
• AranceAMBerrocalALopez-MartinJASafety of vemurafenib in patients with BRAF, V600, mutated metastatic melanoma: the Spanish experienceClin Transl Oncol20161811114726983408
   PubMedGoogle Scholar
• LiuLMayesPAEastmanSThe BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4Clin Cancer Res20152171639165125589619
   PubMed Web of Science ®Google Scholar
• PuzanovICombining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM)J Transl Med20151311225591711
   PubMedGoogle Scholar
• CebolleroAPuértolasTPajaresIComparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanomaMol Clin Oncol20165445846227699043
   PubMedGoogle Scholar
• QueiroloPPicassoVSpagnoloFCombined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanomaCancer Treat Rev201541651952625944484
   PubMed Web of Science ®Google Scholar
• LongGVFlahertyKTStroyakovskiyDDabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 studyAnn Oncol20172871631163928475671
   PubMed Web of Science ®Google Scholar
• JohnsonDBFlahertyKTWeberJSCombined BRAF (dabrafenib) and MEK inhibition (trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitorJ Clin Oncol201432333697370425287827
   PubMed Web of Science ®Google Scholar
• LongGVStroyakovskiyDGogasHDabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialLancet2015386999244445126037941
   PubMed Web of Science ®Google Scholar
• LarkinJAsciertoPADrenoBCombined vemurafenib and cobimetinib in BRAF-mutated melanomaN Engl J Med2014371201867187625265494
   PubMed Web of Science ®Google Scholar
• SchadendorfDAmonkarMMStroyakovskiyDHealth-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanomaEur J Cancer201551783384025794603
   PubMed Web of Science ®Google Scholar
• RobertCKaraszewskaBSchachterJImproved overall survival in melanoma with combined dabrafenib and trametinibN Engl J Med20153721303925399551
   PubMed Web of Science ®Google Scholar
• CorcoranRBAtreyaCEFalchookGSCombined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancerJ Clin Oncol201533344023403126392102
   PubMed Web of Science ®Google Scholar
• FlahertyKTInfanteJRDaudACombined BRAF and MEK inhibition in melanoma with BRAF V600 MutationsN Engl J Med2012367181694170323020132
   PubMed Web of Science ®Google Scholar
• PatelBGAhmedKAJohnstonePAInitial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastasesMelanoma Res201626438238826926151
   PubMed Web of Science ®Google Scholar
• SchmittRJKreidlerSMGlueckDHCorrelation between early FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanomaNucl Med Commun201637212212826440571
   PubMedGoogle Scholar
• KimACohenMSThe discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanomaExpert Opin Drug Discov201611990791627327499
   PubMed Web of Science ®Google Scholar
• DossettLAKudchadkarRRZagerJSBRAF and MEK inhibition in melanomaExpert Opin Drug Saf201514455957025648338
   PubMed Web of Science ®Google Scholar
• RichmanJMartinliberalJDiemSBRAF and MEK inhibition for the treatment of advanced BRAF mutant melanomaExpert Opin Pharmacother20151691285129726001180
   PubMed Web of Science ®Google Scholar
• WelshSJCorriePGManagement of BRAF and MEK inhibitor toxicities in patients with metastatic melanomaTher Adv in Med Oncol20157212213625755684
   PubMed Web of Science ®Google Scholar
• PintoRStrippoliSSummaSDMicroRNA expression in BRAF-mutated and wild-type metastatic melanoma and its correlation with response duration to BRAF inhibitorsExpert Opin Ther Targets20151981027103526156293
   PubMed Web of Science ®Google Scholar
• JohnsonASCrandallHDahlmanKPreliminary results from a prospective trial of preoperative combined BRAF, and MEK-targeted therapy in advanced BRAF, mutation-positive melanomaJ Am Coll Surg2015220458159325797743
   PubMed Web of Science ®Google Scholar
• GallikerNAMurerCKamarashevJClinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitorEur J Dermatol201525217718025788221
   PubMedGoogle Scholar
• KhojaLHoggDDabrafenib in the treatment of metastatic or unresectable melanomaExpert Rev Anticancer Ther201515326527625711514
   PubMed Web of Science ®Google Scholar
• DhillonSDabrafenib plus trametinib: a review in advanced melanoma with a BRAF, V600, mutationTarget Oncol201611341742827246822
   PubMedGoogle Scholar
• TietzeMJKHepptMGrafSAAktuelle und neue Standards in der therapieInfo Onkologie20151884046
   Google Scholar
• HermsFKramkimelNRegnierrosencherEAge and clear eyes are associated with an increased risk of cutaneous squamous cell carcinomas in vemurafenib-treated melanoma patientsMelanoma Res201626548749127261949
   PubMedGoogle Scholar
• SchmidSSianoMJoergerMResponse to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinomaLung Cancer2015871858725466451
   PubMed Web of Science ®Google Scholar